200,000 Shares in Kronos Bio, Inc. (NASDAQ:KRON) Acquired by Deltec Asset Management LLC

Deltec Asset Management LLC bought a new position in Kronos Bio, Inc. (NASDAQ:KRON) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 200,000 shares of the company’s stock, valued at approximately $190,000.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Piper Sandler downgraded Kronos Bio from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $6.00 to $1.00 in a report on Thursday, November 14th. TD Cowen downgraded Kronos Bio from a “buy” rating to a “hold” rating in a research note on Thursday, November 14th.

Kronos Bio Price Performance

KRON stock opened at $0.99 on Wednesday. Kronos Bio, Inc. has a 12 month low of $0.69 and a 12 month high of $1.60. The company has a market capitalization of $59.78 million, a P/E ratio of -0.69 and a beta of 1.80. The firm’s fifty day simple moving average is $0.98 and its 200-day simple moving average is $0.99.

Kronos Bio Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.